From Guaiac to Immune Fecal Occult Blood Tests: The Emergence of Technology in Colorectal Cancer Screening

Gastroenterology Nursing

Volumn 28, Issue 2, 2005, Pages 90-96

  Greenwald, Beverly ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM SULFATE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENEMA; GUAIAC;

AGE; AGED; BIOMEDICAL TECHNOLOGY ASSESSMENT; COLONOSCOPY; COLORECTAL TUMOR; ECONOMICS; HUMAN; IMMUNOCHEMISTRY; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; MIDDLE AGED; OCCULT BLOOD; PATIENT SELECTION; PRACTICE GUIDELINE; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; STANDARD;

AGE FACTORS; AGED; BARIUM SULFATE; COLONOSCOPY; COLORECTAL NEOPLASMS; CONTRAST MEDIA; ENEMA; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; GUAIAC; HUMANS; IMMUNOCHEMISTRY; INDICATORS AND REAGENTS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PATIENT SELECTION; PRACTICE GUIDELINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 21244436703     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/00001610-200503000-00002     Document Type: Article

References (55)

1. Agency for Health Care Policy and Research (AHCPR). (2003).
2. Ahlquist, D. A. (2002). Stool-based DNA tests for colorectal cancer: Clinical potential and early results. Reviews in Gastroenterological Disorders, 2(Suppl. 1), S20-S26.
3. Ahlquist, D. A., Wieand, H. S., Moertel, C. G., McGill, D. B., Loprinzi, C. L., O'Connell, M. J., et al. (1993). Accuracy of fecal occult blood screening for colorectal neoplasia. Journal of the American Medical Association, 269(10), 1262-1267.
4. Allison, J. E., Tekawa, I. S., Ransom, L. J., & Adrain, A. L. (1996). A comparison of fecal occult-blood tests for colorectal-cancer screening. The New England Journal of Medicine, 334(3), 155-159.
5. Bini, E. J., Rajapaksa, R. C., & Weinshel, E. H. (1999). The findings and impact of nonrehydrated guaiac examination of the rectum (FINGER) study: A comparison of 2 methods of screening for colorectal cancer in asymptomatic average-risk patients. Archives of Internal Medicine, 159(17), 2022-2026.
6. Bleiberg, H. (2002). Hemoccult should no longer be used for the screening of colorectal cancer. Annals of Oncology, 13(1), 44-46.
7. Brooks, D. (2004). Colon cancer screening: The right tests. The Clinical Advisor, 7(4), 23-31.
8. Burke, C. A., Tadikonda, L., & Machicao, V. (2001). Fecal occult blood testing for colorectal cancer screening: Use the finger. American Journal of Gastroenterology, 96(11), 3175-3177.
9. Castiglione, G., Grazzini, G., Miccinesi, G., Rubeca, T., Sani, C., Turco, P., & Zappa, M. (2002). Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. Journal of Medical Screening, 9(3), 99-103.
10. Centers for Disease Control and Prevention. (2003).
11. Cole, S. R., & Young, G. P. (2001). Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Medical Journal of Australia, 175(4), 195-198.
12. Cole, S. R., Young, G. P., Esterman, A., Cadd, B., & Morcom, J. (2003). A randomized trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. Journal of Medical Screening, 10(3), 117-122.
13. Crespi, M., & Lisi, D. (2002). Is colorectal cancer screening by fecal occult blood feasible? Annals of Oncology, 13(1), 47-50.
14. Digital rectal exam may improve fecal occult blood test compliance. (2001). Family Practice News, 31(3), 14.
15. Enterix's new colorectal cancer screening test receives FDA clearance. (2001).
16. Fecal globin, immunochemistry (InSure) test summary. (2003).
17. Final 2003 Medicare physician fee schedule enables consideration of InSure for colorectal cancer screening. (2002).
18. Fleisher, M., & Schoengold, R. F. (2003). Occult blood. In J. H. Nichols (Ed.), Point-of-care testing: Performance improvement and evidence-based outcomes (pp. 325-351). New York: Marcel Dekker, Inc.
19. Fleisher, M., Winawer, S. J., Zauber, A. G., Smith, C., Schwartz, M. K., & The National Polyp Study Work Group. (1991). Accuracy of fecal occult blood test interpretation. Annals of Internal Medicine, 114(10), 875-876.
20. Greegor, D. H. (1967). Diagnosis of large-bowel cancer in the symptomatic patient. Journal of the American Medical Association, 201(12), 943-945.
21. Greegor, D. H. (1971). Occult blood testing for detection of asymptomatic colon cancer. Cancer, 28(1), 131-134.
22. Helm, J., Choi, J., Sutphen, R., Barthel, J. S., Albrecht, T. L., & Chirikos, T. N. (2003). Current and evolving strategies for colorectal cancer screening. Cancer Control, 10(3), 193-204.
23. InSure home: FAQ. (2003).
24. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., et al. (2004). Cancer statistics, 2004. CA: A Cancer Journal for Clinicians, 54(1), 8-29.
25. Lang, C. A., & Ransohoff, D. F. (1994). Fecal occult blood screening for colorectal cancer: Is mortality reduced by chance selection for screening colonoscopy? Journal of the American Medical Association, 271(13), 1011-1013.
26. Levin, B., Brooks, D., Smith, R. A., & Stone, M. (2003). Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA: A Cancer Journal for Clinicians, 53(1), 44-55.
27. Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. New England Journal of Medicine, 328(19), 1365-1371.
28. Mandel, J. S., Church, T. R., Bond, J. H., Ederer, F., Geisser, M. S., Mongin, S. J., et al. (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer. New England Journal of Medicine, 343(22), 1603-1607.
29. Mitka, M. (2003). Colon cancer screening guidelines stress initial test's importance. Journal of the American Medical Association, 289(9), 1089-1090.
30. Nakama, H., Fattah, A., Zhang, B., Uehara, Y., & Wang, C. (2000). A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Hepatogastroenterology, 47(32), 386-389.
31. Nakama, H., Fattah, A. S., Zhang, B., & Kamijo, N. (2000). Digital rectal examination sampling of stool is less predictive of significant colorectal pathology than stool passed spontaneously. European Journal of Gastroenterology and Hepatology, 12(11), 1235-1238.
32. Nakama, H., Kamijo, N., Fujimori, K., Horiuchi, A., Fattah, A. S. M. A., & Zhang, B. (1996). Characteristics of colorectal cancer with false negative result on immunochemical faecal occult blood test. Journal of Medical Screening, 3(3), 115-118.
33. Nakama, H., Zhang, B., Fattah, A., & Kamijo, N. (2001). Does stool collection method affect outcomes in immunochemical fecal occult blood testing? Diseases of the Colon and Rectum, 44(6), 871-875.
34. Pignone, M., Campbell, M. K., Carr, C., & Phillips, C. (2001). Meta-analysis of dietary restriction during fecal occult blood testing. Effective Clinical Practice, 4(4), 150-156.
35. Ransohoff, D. F., & Lang, C. A. (1991). Screening for colorectal cancer. New England Journal of Medicine, 325(1), 37-41.
36. Ransohoff, D. F., & Lang, C. A. (1996). Improving the fecal occult-blood test. New England Journal of Medicine, 334(3), 189-190.
37. Ransohoff, D. F., & Lang, C. A. (1997a). Clinical guideline part I: Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Annals of Internal Medicine, 126(10), 808-810.
38. Ransohoff, D. F., & Lang, C. A. (1997b). Clinical guideline part II: Screening for colorectal cancer with the fecal occult blood test, a background paper. Annals of Internal Medicine, 126(10), 811-822.
39. Rex, D., Rahmani, E. Y., Haseman, J. H., Lemmel, G. T., Kaster, S., & Buckley, J. S. (1997). Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology, 112(1), 17-23.
40. Rex, D. K., Cutler, C. S., Lemmel, G. T., Rahmani, E. Y., Clark, D. W., Helper, D. J., et al. (1997). Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology, 112(1), 24-28.
41. Reyes, H. R., & Bean, P. (2003).
42. Robinson, M. H. E., Pye, G., Thomas, W. M., Hardcastle, J. D., & Mangham, C. M. (1994). Hemoccult screening for colorectal cancer: The effect of dietary restriction on compliance. European Journal of Surgical Oncology, 20(5), 545-548.
43. Saito, H. (1996). Screening for colorectal cancer by immunochemical fecal occult blood testing. Japanese Journal of Cancer Research, 87(10), 1011-1024.
44. Saito, H. (2000). A case-control study evaluating occult blood screening for colorectal cancer with Hemoccult test and an immunochemical hemagglutination test. Oncology Reports, 7(4), 815-819.
45. Sharma, V. K., Corder, F. A., Fancher, J., & Howden, C. W. (2000). Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and the use of the fecal occult blood test. American Journal of Gastroenterology, 95(12), 3629-3632.
46. Smith, R. A., Cokkinides, V., & Eyre, H. J. (2003). American Cancer Society guidelines for the early detection of cancer, 2003. CA: A Cancer Journal for Clinicians, 53(1), 27-43.
47. Smith, R. A., Cokkinides, V., & Eyre, H. J. (2004). American Cancer Society guidelines for the early detection of cancer, 2004. CA: A Cancer Journal for Clinicians, 54(1), 41-52.
48. Smith, R. A., von Eschenbach, A. C., Wender, R., Levin, B., Byers, T., Rothenberger, D., et al. (2001). American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA: A Cancer Journal for Clinicians, 51(1), 38-75.
49. Study shows 85% sensitivity with non-invasive colorectal cancer screening test. (2003).
50. Tagore, K. S., Lawson, M. J., Yucaitis, J. A., Gage, R., Orr, T., Shuber, A. P., & Ross, M. E. (2003). Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clinical Colorectal Cancer, 3(1), 47-53.
51. Testing stool for occult blood at the time of DRE does not increase false-positives. (2000). Physician Assistant, 24(4), 34.
52. United States Preventive Services Task Force (USPSTF). (2002). Screening for colorectal cancer: Recommendation and rationale. Annals of Internal Medicine, 137(2), 129-131.
53. van Ballegooijen, M., Habbema, J. D. F., Boer, R., Zauber, A. G., & Brown, M. L. (2003). Report to the Agency for Healthcare Research and Quality: A comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population.
54. Wineman, A. P. (2003). Screening for colorectal cancer: Guidelines for choosing the appropriate test for each patient. Postgraduate Medicine, 113(2), 49.
55. Wong, W. M., Lam, S. K., Cheung, K. L., Tong, T. S. M., Rozen, P., Young, G. P., et al. (2003). Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer, 97(10), 2420-2424.